[Fundamental and clinical studies on cefminox]

Area of Science:

• Pharmacology
• Pediatric Infectious Diseases

Background:

• Cefminox (CMNX) is a novel cephalosporin antibiotic.
• Evaluating CMNX in pediatric infections is crucial for establishing its clinical utility.

Observation:

• Two pediatric patients (9 and 11 years) received intravenous CMNX (20 mg/kg).
• Serum concentrations, urinary recovery, and elimination half-life were monitored.
• Therapeutic outcomes and adverse effects were systematically recorded.

Findings:

• Mean serum concentrations declined from 178.7 µg/ml at 15 min to 5.3 µg/ml at 6 hours.
• The elimination half-life of CMNX in serum was 1.36 hours.
• High urinary recovery (86.5% at 6 hours) and a 95% efficacy rate were observed, with only minor side effects like S-GOT elevation and drug fever in 2 patients.

Implications:

• Cefminox exhibits favorable pharmacokinetic properties in children.
• The high efficacy and safety profile suggest CMNX is a promising therapeutic option for pediatric infections.
• Further large-scale studies are warranted to confirm these findings across diverse pediatric populations.